Clinical Trials
76 trialsTesting the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
National Cancer Institute (NCI)
RAINFOL-01
Genmab
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
TroFuse-033
Merck Sharp & Dohme LLC
Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
M.D. Anderson Cancer Center
RAINBO
Leiden University Medical Center
FIERCE
University of Oklahoma
DE-01
AstraZeneca
KEYNOTE-C93
Merck Sharp & Dohme LLC
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
Chemotherapy or Observation in Stage I-II Intermediate or High Risk Endometrial Cancer
Danish Gynecological Cancer Group
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
AstraZeneca
QLS5132 Combination Therapy in Advanced Solid Tumors
Qilu Pharmaceutical Co., Ltd.
FONTANA
AstraZeneca
PETRA
AstraZeneca
A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
Memorial Sloan Kettering Cancer Center
LEAP-001
Merck Sharp & Dohme LLC
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Eli Lilly and Company
DUO-E
AstraZeneca
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
GlaxoSmithKline
LEAP-001
Merck Sharp & Dohme LLC
(VELA) Study of BLU-222 in Advanced Solid Tumors
Blueprint Medicines Corporation
Study of AVZO-021 in Patients With Advanced Solid Tumors
Avenzo Therapeutics, Inc.
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Eli Lilly and Company
KEYVIBE-005
Merck Sharp & Dohme LLC
BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer
Bio-Thera Solutions
Combination Chemotherapy With Nintedanib / Placebo in Endometrial Cancer
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
RUBY-J
GlaxoSmithKline
Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer
Seoul National University Hospital
The UPPROACH (Upfront Intensity Modulated Proton Beam Therapy) Approach
University of Maryland, Baltimore
KEYNOTE-B21
Merck Sharp & Dohme LLC
AtTEnd
Mario Negri Institute for Pharmacological Research
Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma
Ohio State University Comprehensive Cancer Center
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
Inspirna, Inc.
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer
Ohio State University Comprehensive Cancer Center
A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor
Huabo Biopharm Co., Ltd.
MK-3475 Immunotherapy in Endometrial Carcinoma
Washington University School of Medicine
QL1706 Combined with Chemotherapy in the Treatment of Recurrent or Metastatic Endometrial Cancer
Peking Union Medical College Hospital
A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
GYNET
NETRIS Pharma
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Tislelizumab in Combination With Chemotherapy as a Neoadjuvant Treatment for Advanced Endometrial Cancer
Zhongnan Hospital
EC-01
Huazhong University of Science and Technology
Vaginal Cuff Brachytherapy Followed by Chemotherapy in Endometrial Cancer
University of Oklahoma
Myeloprotection With Trilaciclib in Pan-cancer Population
Sun Yat-sen University
Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer
Fujian Cancer Hospital
Adjuvant Sequential & Concurrent CarboTaxol + Radiotherapy for High Risk Endometrial Cancer
Loyola University
MITO END-3
National Cancer Institute, Naples